Leber et al. showed that NLRX1 regulated the adaptive response in IBD because a greater number of Th17 and Th1 cells with a higher proliferative capacity appeared in the colon of Nlrx1−/− mice treated with DSS [91]. Here, NLRX1 is linked to inflammatory bowel disease.